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Abstract
Postpartum thyroiditis (PPT) is a triphasic phenomenon that affects women who clinically are
without thyroid disease prior to pregnancy but develop PPT in the first year postpartum or after a
spontaneous/induced abortion (Vimalachandran, 2019). Recognition of thyroid dysfunction and
possible differentials can augment the providers' ability to appropriately counsel and treat the
patient. PPT affects about 5-10% of all women; of those that develop PPT, one in five patients
will develop permanent hypothyroidism and require lifelong treatment (Burman, 2019). The
etiology, risk factors, clinical course, prognosis, and treatment of PPT will be reviewed as it
correlates with the clinical relevance of screening patients for potential thyroid dysfunction.
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Background
Thyroid disorders are among the most common endocrine conditions evaluated and
treated by clinicians during the antenatal and postnatal periods apart from diabetes (Tingi et al.,
2016). Postpartum thyroiditis is an autoimmune destruction of the thyroid gland, which is
characterized by three (triphasic thyroid pattern) phases; thyrotoxic, hypothyroid, and a
euthyroid phase (Pearce, 2015). Physiological changes of the thyroid along with pathological
function are most affected during the antenatal period and the year following parturition resulting
in a combination of increased metabolic demand, often causing an onset, exacerbation, or relapse
of autoimmune diseases (Tingi et al., 2016). Postpartum thyroiditis does not always manifest
clinically, indicating the importance of identification of this differential by the clinician (Gibson
& Nelson-Piercy, 2018).
During a healthy pregnancy, the thyroid increases in size and vascularity, the thyroidstimulating hormone reaches the upper limit of normalcy and decreases while the thyroxine (T4)
and the triiodothyronine (T3) increases by fifty percent (Grossman & Porth, 2014). The increases
in T3 and T4 are needed to maintain free thyroxine (fT4) within normal limits as pregnancy
increases thyroxine-binding globulin giving women a high reserve within the thyroid gland
(Grossman & Porth, 2014). Pregnancy is described as a "biological stress test" by
endocrinologists, and without underlying conditions, the thyroid can compensate "flawlessly"
(Stagnaro-Green et al., 2019). However, thyroid dysfunction antenatal and postnatal is associated
with adverse outcomes for both the mother or baby, including anemia, miscarriage, fetal growth
restriction, gestational diabetes, pre-eclampsia/gestational hypertension, pre-term birth/delivery,
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neurodevelopmental delay, stillbirth, respiratory distress and fetal death (Gibson & NelsonPiercy, 2018; Nguyen & Mestman, 2019; Stagnaro-Green et al., 2019; Yalamanchi & Cooper,
2015)
Pearce (2015) and Vimalachandran (2019) have found that in PPT lymphocytic
inflammation of the thyroid initially leads to a transient thyrotoxicosis which can last two to four
months up to six to nine weeks; symptoms are typically mild and go unnoticed because the
patient is adapting to other physiological changes in the postpartum period with a newborn/baby.
If screened during this time, the T4 can have marked elevation in comparison to T3, and as these
thyroid stores deplete a progression through a euthyroid to hypothyroid phase before thyroid
recovery can occur. One-third of patients will experience the triphasic pattern, and one third can
experience a biphasic pattern with either a thyrotoxicosis or hypothyroidism. The reoccurrence
of PTT has been documented in nearly 70% of diagnosed patients.
Screening for thyroid dysfunction is not routine antenatal, nor postnatal, and is typically
only completed by targeted screening secondary to the patients' risk factors. The goal of this
review is to determine if standardizing routine screening can prevent postpartum mothers from
developing permanent hypothyroidism if screened, diagnosed, and treated within an appropriate
timeframe. Clinical indication for an appropriate postpartum thyroiditis versus hypothyroidism
differential diagnosis is essential due to their potential for different clinical courses and
treatments.
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Case Report
Elizabeth was a 37-year-old patient that presented to the clinic for evaluation of ongoing
fatigue, dry skin, weight gain of 15lbs., and difficulty with memory and concentration. The
patient stated she noticed symptom onset three months prior initially with her weight gain, and
fatigue. The patient did not have any recent changes in her typical day, attended a local gym but
resorted to the sauna due to decreased endurance, and unusual exhaustion. During assessment,
Elizabeth revealed an ongoing inability to stay on task for long periods. She denied any change
in sleep or intake patterns but had been having difficulty passing bowels; denied any OTC
intervention but had increased her water, fruits, and vegetable intake. The patient did have a
primary care provider, which she presented to only when needed, which she contacted before
presenting and had pre-ordered fasting labs completed.
The patient was a G3P3 that was currently breastfeeding - her youngest child was born
nine months ago without complication – her menses are irregular, she contributes this to
breastfeeding, natural family planning with unknown last menstrual cycle. Besides the recent
onset of stated symptoms patient had unremarkable health history, all health maintenance and
immunizations were up to date, no known food, seasonal or drug allergies, and she was only
taking two over the counter medications; a women's multivitamin, and a generic probiotic.
Her physical examination revealed a well-developed and nourished woman, vitals,
130/80 blood pressure, 76 pulse, 16 respiration, 100% on room air, 97.8 tympanic temperature,
71 inches in height, and 81 kilograms in weight. No evidence of thyroid enlargement, tenderness,
nodules or lymphadenopathy, cardiac assessment revealed regular rate and rhythm, no jugular
venous distention, and clear lung sounds bilaterally, normoactive bowel sounds in all four
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quadrants, soft, non-tender, with no masses. The patient did have generalized xerosis cutis; her
affect mildly flat with some forgetfulness, memory, and judgment were appropriate for age.
Elizabeth's diagnostic exam revealed an unremarkable complete blood count (CBC),
comprehensive metabolic panel (CMP), glycated hemoglobin test (HgA1C) of 5.4%, vitamin D
of 40ng/mL, negative urinalysis, human chorionic gonadotropin (hCG), C-reactive protein (CRP)
of 4.0mg/L and a marked elevation of her thyroid-stimulating hormone (TSH) of 7.0mU/L and a
decrease in thyroxine (T4) at 0.25mcg/dL.
Based on Elizabeth's presentation of symptoms, her history, physical exam, and
diagnostic findings, hypothyroidism was suspected. Per Naidu et al. (2019), it is not uncommon
for patients to present with complaints of chronic fatigue, slowed thinking, constipation, dry
skin, menstrual disturbances, and a modest weight gain with primary hypothyroidism. Physical
exam usually reveals dry, coarse, or thickened skin, hair loss, or brittle hair, coarsening of voice,
goiter, periorbital puffiness, swelling of hands, and feet, bradycardia, reduced systolic blood
pressure, or increased diastolic blood pressure and delayed deep tendon reflexes. Diagnostic test
results for hypothyroidism include an elevated TSH, a decreased serum free T4.
However, because Elizabeth was nine months postpartum, she also had clinical suspicion
for the triphasic thyroid hormone pattern of postpartum thyroiditis (PPT). Clinical presentation
of PPT can vary, and because the patient did not have any risk factors before indicating the need
for thyroid function screening antenatal nor postnatal, a thyroid peroxidase (TPO) antibody titer
was added on to her previously collected labs. With the treatment guidelines/indications being
similar for primary hypothyroidism and symptomatic postpartum thyroiditis the patient was
treated with 25mcg of daily Levothyroxine and directed to return for follow-up in four to six
weeks for a recheck on her TSH and T4 and potential increase of her medication until a
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therapeutic index is reached or she can discontinue medication therapy (Naidu et al., 2019;
Vimalachandran, 2019). Levothyroxine excretion, while breastfeeding reviewed with the patient
and not contraindicated (Hale & Rowe, 2019).
Literature Review
Research was conducted through the University of North Dakota's School of
Medicine & Health Sciences Library, with primary search through Clinical Key, PubMed, and
CINAHL. Postpartum thyroiditis and hypothyroidism were used with identified MeSH
subheadings, complications, diagnosis, drug therapy, epidemiology, immunology, mortality,
prevention and control, pharmacokinetics, pharmacology, statistics, and numerical data, and
trends. Descriptors included English, female adults (age 19-44), publication within the past five
years in the form of – Systematic Reviews, Meta-analysis, Practice Guidelines, Case Reports,
Literature, and Narrative Reviews. Limitations yielded near 300 results; factors requiring
removal included non-topic correlation, no abstract, no full-text availability, professional reply
excerpts, duplication, and exceptional circumstance and consideration of interlibrary loan
unavailability. Fifteen articles were identified with relevancy for this review.
In order to avoid adverse maternal and fetal outcomes, early diagnosis and management
of thyroid disruption, both antenatal and postnatal is vital. Due to the wide range of physiological
changes that are experienced during pregnancy with the thyroid gland and hormones, diagnosis
can often be challenging for the clinician. Clinical symptom presentation for postpartum
thyroiditis can vary depending on the course of phase in dysfunction; symptoms of the
hyperthyroid phase are often described as mild with generalized complaints of fatigue,
palpitations, irritability, sleep disturbance, increased sweating, and heat intolerance (Kellerman,
2020; Nguyen & Mestman, 2019; Vimalachandran, 2019). Within the hypothyroid phase patients
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typically can present with complaints of constipation, irregular menstrual bleeding, impaired
memory, or concentrations, fatigue, generalized aches, and pains, weakness, dry skin, hair loss,
cold intolerance, difficulty with weight loss, or mild weight gain (Kellerman, 2020; Nguyen &
Mestman, 2019; Vimalachandran, 2019). The etiology with thyroid dysfunction and postpartum
depression remains unclear; however, patients with postpartum depression are recommended to
be screened for a thyroid disorder (Iwen & Lehnert, 2018). Postpartum thyroiditis can impact
milk letdown and the mother's ability to breastfeed successfully; women that demonstrate poor
lactation should also be evaluated for thyroid disorders (Nguyen & Mestman, 2019).
The physical exam of PPT is similar to those that occur in nonpregnant patients and is
dependent on the phase in which the woman is presenting; examination of the thyroid may reveal
a diffusely enlarged painless gland with a pebbly like texture, a painless small nontender firm
goiter, or the thyroid gland can be normal without any palpable masses (Kellerman, 2020;
Vimalachandran, 2019). Signs of hyperthyroidism may reveal hyperreflexia, tachycardia, with or
without atrial fibrillation; a hypothyroid presentation may include delayed reflexes, nonpitting
edema, dry skin, coarse/thickened skin, reduced systolic blood pressure, increased diastolic
blood pressure, and bradycardia, or the patient could have a benign exam and present without
any signs or symptoms suggestive of a thyroid disorder (Kellerman, 2020; Naidu et al., 2019;
Vimalachandran, 2019). Distinguishing differences in hyper/hypothyroidism from healthy
physiological changes in pregnancy and the postpartum period can be difficult; however, features
suggestive of thyroid disorders that preceded pregnancy indicate a need for screening (Gibson &
Nelson-Piercy, 2018).
Due to the complexity of trimester-specific reference ranges for testing of thyroid
function, this report only reflects postpartum screening and an antibody predictor of PPT within
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the first trimester with normal reference ranges. Interpretation of diagnostic laboratory testing for
hypothyroidism usually includes an elevated TSH and decreased serum free T4, with an antiTPO antibody positivity marker being the best predictor of PPT (Vimalachandran, 2019).
However, the screening of asymptomatic antenatal and postnatal women for thyroid disruption
remains controversial and not routinely recommended allowing variation in diagnosing and
management practices.
Guidelines & Recommendations
Current guideline trends gathered within the literature presume a targeted screening
approach rather than a universal approach that identifies women that are at high risk for
developing thyroid dysfunction during pregnancy or in the postnatal period. Targeted screening
is guided on three principles per Stagnaro-Green et al., (2019), risk factors identify patients that
are predisposed to the disease of interest, screening individuals with those risk factors can help
identify a majority of patients with a lower cost derived with targeted screening versus the
downside of false positives and negatives. Kellerman (2019) and Mcdermott (2019) also found
that the debate on universal screening varies from society to society with substantial opinion
consideration from endocrinologists, obstetricians, gynecologists, and governmental agencies;
however, targeted screening for predisposed patients all trend in similarity.
The American College of Obstetricians and Gynecologists (ACOG) recommendations
require testing of high-risk women that are symptomatic or have a personal history of any
autoimmune diseases (Yalamanchi & Cooper, 2015). The Endocrine Society supports a "casefinding" approach in conjunction with generalized guidelines across clinical resources such as
up-to-date and 5minute consult which includes: patients that live in areas of moderate to severe
iodine insufficiency, symptomatic, familial, or personal history of thyroid disease, or have any of
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the following: thyroid peroxidase (TPO) antibodies, goiter, >30 years of age, diabetes, head, or
neck irradiation, recurrent miscarriages, preterm deliveries, two, or more pregnancies, obesity,
infertility, prior thyroid surgery (Burman, 2019; Donnay Candil, 2015; Naidu, 2019; Ross, 2020;
Smith et al., 2017 Vimalachandran, 2010; Yalamanchi & Cooper, 2015). The American Thyroid
Association (ATA) recommendations are similar of the Endocrine Society and clinical references
with the addition that patients who have received recent administration of iodinated radiologic
contrast agents or are currently prescribed amiodarone or lithium receive screening for thyroid
dysfunction in the first trimester (Yalamanchi & Cooper, 2015).
Studies have shown that a targeted screening and case finding approach may fail to
identify near 30-80% of thyroid dysfunction in the antenatal and postnatal periods (Pearce, 2015;
Smith et al., 2017). Nevertheless, a unanimous consensus remains about testing asymptomatic
non-at-risk patients, with interest, however, regarding their availability, reliability, and potential
for cost-effectiveness versus not testing patients. The recommendation for screening of thyroid
dysfunction in high-risk patients should be completed in the first trimester with a thyroid
peroxidase antibody (TPO-Ab) titer. The TBO can detect inflammation of the thyroid gland and
can also predict dysfunction, autoimmune disorder(s), and other non-organ-specific antibodies,
which can precipitate adverse pregnancy complications (Borba et al., 2019; Pearce, 2015). Per
Vimalachandran (2019), TBO-Ab+ is the most predictive marker for PPT; women known to
have the presence of antibodies within the first trimester should have their thyroid-stimulating
hormone (TSH) measured at six to twelve weeks' gestation and repeated at six months
postpartum or as clinically indicated. Women with positive antibodies usually have
hypothyroidism between three to eight months postpartum, with 80% of them spontaneously
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resolving at one year postpartum. However, of those that do not resolve 30-50% of them can
develop permanent hypothyroidism within ten years.
Detection
Though there are not universal screening guidelines for asymptomatic antenatal and
postnatal women, LeFevre (2015) discusses the theory of the pros and cons of detection and why
they need to be considered. The benefits of early detection, like many conditions, may be
beneficial for long term morbidity and mortality from permanent hypothyroidism, cancers,
and/or cardiovascular diseases. The U.S Preventive Services Task Force (USPSTF) has found
inadequacies in screening asymptomatic women for thyroid dysfunction in correlation to
beneficial cardiovascular disease outcomes; however, they concluded early detection and
treatment does not have clinically meaningful improvements in blood pressure, body mass index
(BMI), bone density, lipid levels, or cognitive function. Harms of early detection included falsepositive results, psychological effects of patient labeling/diagnosing, over-diagnosing,
overtreating, and being wrongly treated by inexperienced clinicians added Stagnaro-Green et al.,
(2019). Harmful impact of late detection can cause a multitude of complications including
persistent hypothyroidism, congenital disabilities, goiter, cardiac issues, infertility, and
myxedema (Burman, 2020).
Special considerations
Factors that can influence a patients’ TSH results include timing, prescribed medications,
over-the-counter supplements, and their current state of health. In times of illness, during
pregnancy, and in the postpartum period or when a patient may have other comorbidities such as
protein malnutrition, hepatic failure, or nephrotic syndrome evaluation of thyroxine T4 and
triiodothyronine T3 would be indicated (Naidu et al., 2019; Nguyen & Mestman, 2019). The
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thyroid-stimulating hormone is in a state of constant fluctuation, proving that it is not the best
lone indicator of overall thyroid function in the postpartum period; once a patient reaches the
hypothyroid state during PPT, there is a marked decrease in the T4 and T3 (Burman, 2019;
Naidu, 2019; Paulson, 2019; Ross, 2020; Vimalachandran, 2010; Yalamanchi & Cooper, 2015).
Nguyen and Mestman (2019) also stated that when a TPO-Ab+ is positive, the thyroglobulin
antibody (TG-Ab) may also be positive; however, it is not a typical diagnostic marker of PPT.
Lastly, in the postpartum period, thyroid hormone autoantibodies (TH-Ab) can interfere with
appropriate evaluation of thyroid function due to their elevated concentrations and binding
properties but resolve by 48 weeks postpartum. No reports have concluded their prediction of
PPT.
Nyugen and Mestman (2019) concluded that studies evaluating the prevention of PPT
have been unsuccessful and have not been able to prove a reduction of risk in developing
permanent hypothyroidism if diagnosed and treated early augmenting nonuniversal routine
screening guidelines. Hypothyroidism has been reported in 2-21% of patients one year
postpartum with reports up to 54%. Thirty to fifty percent of women that had PPT reported a
diagnosis of permanent hypothyroidism as early as three years post-delivery, up to 12 years.
Evaluation
Due to the complexity of evaluating thyroid function in the postpartum period and nonuniversal screening guidelines, Paulson (2019) describes a common discussion across the
literature to not treat pharmacologically based on one set of diagnostic results if the patient is
asymptomatic because of the transient prediction of returning to euthyroid state and the
sensitivity and specificity of TSH levels. Recommendation to repeat a TSH, or fT4 is based on
slight deviation out of reference range which should be completed at the same laboratory; please
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note diagnosing hypothyroidism and evaluating TSH levels to assess replacement therapy are not
included in this literature and do not reflect the prior statements (Paulson, 2019). However, the
USPSTF states that TSH is the gold standard for detecting thyroid dysfunction and that it should
be performed at three to six-month intervals to rule out or confirm abnormal findings (LeFevre,
2015). Optimal screening intervals and frequencies are unknown.
Another statement that should be taken into consideration by Tandeter and Fraenkel
(2018) indicates that once a patient is pharmaceutical, they are always pharmaceutical; with
clinical guidelines to start therapies, there are not always clear cut guidelines to discontinue
therapy once a therapeutic index is reached. The literature shines a light on the recent publication
of medications that should or could be stopped, such as antihypertensives and statins. However,
in patients with any variation of hypothyroidism, these patients usually receive lifelong therapies
despite the restoration of thyroid function. Variances within the literature describe select few
patients that are treated with levothyroxine and have been able to titrate off the medication once
a euthyroid level is reached – variations of patients include deficiency in vitamin d, iodine uptake
and other autoimmune disorders respectfully (Burman, 2019; Naidu, 2019; Paulson, 2019; Ross,
2020; Vimalachandran, 2010; Yalamanchi & Cooper, 2015).
Treatment
Approaching the patient with PPT is primarily based on the clinicians' index of suspicion
for hypothyroidism and correlation with clinical symptoms, physical examination, and laboratory
values. Levothyroxine is the principle monotherapy treatment for hypothyroidism but is
dependent on different factors. Asymptomatic patients with mild thyroid function test
abnormalities do not require pharmacological therapy; however, they should have their TSH and
free T4 monitored for evaluation of resolution, or to detect permanent hypothyroidism (Burman,
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2019). Symptomatic hypothyroidism or a TSH above 10mU/L requires T4 replacement;
dependent on the degree of elevation determines the appropriate dose of Levothyroxine
(Burman, 2019).
The prediction of permanent hypothyroidism is inefficacious; therefore, patients are
titrated off at 12 months postpartum for a reevaluation of spontaneous resolution of their thyroid
function, those that do not have spontaneous resolution of thyroid function require therapy and
annual evaluations' of TSH as indicated (Burman, 2019; Gibson & Nelson-Piercy, 2018; Pearce,
2015; Vimalachandran, 2019). Patients that desire future pregnancies should receive education
and the recommendation to continue T4 supplementation along with breastfeeding women
(Nguyen & Mestman, 2019).
Conclusion
Throughout the literature, the question remains, should we be screening non-at-risk
postpartum mothers for thyroid dysfunction? There seems to be insufficient data supporting the
recommendation for routine screening in asymptomatic patients that are not predisposed to
thyroid disorders. In the absence of strong evidence indicating a need for universal routine
screening, the decision to screen, treat, and manage this condition lies primarily on an
appropriate history and physical by the clinician. Mandated screening does not exist; however,
recommended screening of thyroid function does occur when patients reach certain ages'
dependent on the guidelines a clinician chooses to follow (Naidu et al., 2019). The literature on
screening asymptomatic patients for thyroid dysfunction was partially scarce, though the clinical
question prompts an appropriate differential diagnosis consideration when treating women of
childbearing age.
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Learning Points
•

Understanding the physiological changes and pathological function of the thyroid and its
dysfunction that a patient may encompass during pregnancy is vital for the best maternal
and fetal outcomes.

•

Though there is conflicting research on the indication for routine screening of postpartum
mothers, the clinician must be able to identify this differential within the practice setting
when working with antenatal and postnatal women.

•

If a clinician chooses to routinely screen patients within their practice setting, the patient
should be informed and fully aware of the potential clinical benefits and harms of
screening within the antenatal and postnatal periods.

•

If the clinician chooses to screen asymptomatic postnatal women, be confident in the
clinical decision to treat or not treat. (If you screen, know why you are screening, and
what you are going to do about it).

•

Currently, no known interventions exist to prevent hypothyroidism (Kellerman, 2019).
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